Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NB1011

Known as: NB 1011, NB101.1 
A novel small molecule, and a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine with antitumor property. NB1011 is selectively… Expand
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

Brivudine Phosphoramidate

Broader (1)

Bromodeoxyuridine
analogs & derivativesthymectacin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Antiviral drug design, synthesis and biological evaluation for treatment of Hepatitis C virus
Hepatitis C virus is an infectious disease affecting millions of people worldwide and causing chronic liver disease. The current… Expand
  • figure 1.1
  • figure 1.2
  • figure 1.4
  • figure 1.5
  • figure 1.6
2005
2005
NAPHTHYL PHOSPHORAMIDATE DERIVATIVES OF BVdU AS POTENTIAL ANTICANCER AGENTS: DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION
The phosphoramidate technology we have developed has been recently applied to BVdU, leading to NB1011 (NewBiotics Inc… Expand
2004
2004
Enzyme catalyzed therapeutic activation of NB1011 (N) selectively targets thymidylate synthase (TS)-overexpressing tumor cells: Phase I results
3144 Background: Resistance to fluoropyrimidines (FP) is associated with increased expression of TS. N is a pronucleotide analog… Expand
2003
2003
Cellular transformation of the investigational new anticancer drug NB1011, a phosphoramidate of 5-(2-bromovinyl)-2'-deoxyuridine, results in modification of cellular proteins not DNA.
NB1011 [E-5-(2-bromovinyl)-2'-deoxyuridine-5'-(L-methylalaninyl)-phenylphosphoramidate], a phosphoramidate prodrug of E-5-(2… Expand
2003
2003
Kinetic properties of human thymidylate synthase, an anticancer drug target.
We have determined the kinetic parameters of human recombinant thymidylate synthase (hrTS) with its natural substrate, dUMP, and… Expand
2003
2003
Formulation development of a nucleotide phosphoramidate
To develop a shelf-stable formulation of a cancer treatment under study, the authors evaluated three approaches: cosolvent… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • table III
2002
2002
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011
NB1011, a novel anticancer agent, targets tumor cells expressing high levels of thymidylate synthase (TS). NB1011 is converted… Expand
2002
2002
Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.
NB1011, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. NB1011… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2001
2001
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.
The in vivo administration of enzyme-inhibiting drugs for cancer and infectious disease often results in overexpression of the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2001
2001
A novel approach to thymidylate synthase as a target for cancer chemotherapy.
Tumor cell resistance to fluoropyrimidines and other inhibitors of thymidylate synthase (TS) is a serious problem often… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE